Archives 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 May 24, 2021 Director Retirement Read More April 29, 2021 FINAL RESULTS ANNOUNCEMENT for the twelve months ended 31 December 2020 Read More February 09, 2021 Lupuzor™ scheduled to commence international Phase 3 trial in Lupus patients in H2 2021 Read More January 18, 2021 Appointment of Company Secretary Read More January 04, 2021 Lanstead Capital TR1 Read More December 03, 2020 ImmuPharma to present at Biotech Showcase™ Digital 2021 Read More November 30, 2020 Total Share Capital Notification Read More November 26, 2020 Grant of Share Options & PDMR dealing Read More November 24, 2020 Conversion of Convertible Security Read More November 23, 2020 Conversion of Convertible Security Read More November 20, 2020 FDA confirms 4 December 2020 for Type ‘A’ meeting to discuss guidance on forthcoming international Phase 3 trial of Lupuzor™ in Lupus patients Read More November 19, 2020 Total Share Capital Notification Read More 12345…17
February 09, 2021 Lupuzor™ scheduled to commence international Phase 3 trial in Lupus patients in H2 2021 Read More
November 20, 2020 FDA confirms 4 December 2020 for Type ‘A’ meeting to discuss guidance on forthcoming international Phase 3 trial of Lupuzor™ in Lupus patients Read More
